{
    "medicine_id": "ff8d1faad7e3740c662add390128b41b1a15065d",
    "platform_id": "DB04869",
    "metadata": {
        "name": "Tasigna 200 mg Capsule",
        "composition": "200 mg Olcegepant",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of migraine headaches",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Olcegepant is a calcitonin gene related peptide CGRP antagonist In preclinical studies olcegepant attenuated arterial dilation induced by CGRP or electrical stimulation In a phase II clinical trial olcegepant reduced the severity of headache in 60 of migraine sufferers and met secondary endpoints including headache free rate and rate of sustained response Only mild to moderate transient adverse events were observed with no adverse cardiovascular symptoms reported The compound appears to be an effective anti migraine medication that is well tolerated and does not display the vasoconstrictive effect that precludes the use of triptans and dihydroergotamine in certain patients",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}